Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05605535Phase 2Active Not Recruiting

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Role: lead

NCT04498117Phase 3Active Not Recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Role: lead

NCT05335993Phase 2Active Not Recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Role: lead

NCT04938583Phase 1Unknown

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Role: lead

NCT05407584Phase 2Unknown

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Role: collaborator

NCT04620954Phase 1Unknown

Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Role: collaborator

NCT03162562Phase 1Terminated

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Role: lead

All 7 trials loaded